Renaissance Technologies LLC Increases Position in INmune Bio, Inc. (NASDAQ:INMB)

Renaissance Technologies LLC lifted its holdings in shares of INmune Bio, Inc. (NASDAQ:INMB) by 73.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,800 shares of the company’s stock after acquiring an additional 78,600 shares during the quarter. Renaissance Technologies LLC owned 0.84% of INmune Bio worth $868,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Wells Fargo & Company MN grew its stake in INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock valued at $30,000 after purchasing an additional 2,155 shares during the period. Geode Capital Management LLC grew its position in INmune Bio by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 363,602 shares of the company’s stock valued at $1,698,000 after buying an additional 19,136 shares during the period. Diametric Capital LP increased its holdings in INmune Bio by 24.6% during the fourth quarter. Diametric Capital LP now owns 36,699 shares of the company’s stock worth $171,000 after buying an additional 7,244 shares during the last quarter. JPMorgan Chase & Co. raised its position in INmune Bio by 93.0% in the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock worth $53,000 after acquiring an additional 5,461 shares during the period. Finally, LPL Financial LLC raised its position in INmune Bio by 33.0% in the fourth quarter. LPL Financial LLC now owns 19,072 shares of the company’s stock worth $89,000 after acquiring an additional 4,730 shares during the period. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Price Performance

INmune Bio stock opened at $7.59 on Friday. The firm has a market capitalization of $174.45 million, a P/E ratio of -3.48 and a beta of 1.86. INmune Bio, Inc. has a one year low of $4.32 and a one year high of $11.99. The business has a fifty day moving average price of $7.76 and a 200-day moving average price of $6.77.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.14. Sell-side analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Maxim Group raised their price target on shares of INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Scotiabank raised their target price on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 11th. Rodman & Renshaw started coverage on INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, INmune Bio currently has an average rating of “Buy” and a consensus price target of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.